Tekcis 2-50 Gbq Radionuclide Generator
(ho-
* Molecular
Package leaflet: Information for the patient
Tekcis 2-50 GBq radionuclide generator
Sodium pertechnetate (99mTc)
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
- If you get any side effects talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet.
What is in this leaflet
1. What Tekcis is and what it is used for.
2. What you need to know before the sodium pertechnetate (99mTc) solution obtained with Tekcis is used.
3. How sodium pertechnetate (99mTc) solution obtained with Tekcis is used.
4. Possible side effects.
5. How Tekcis is stored
6. Contents of the pack and other information
1. What Tekcis is and what it is used for
This medicine is a radiopharmaceutical product for diagnostic use only.
Tekcis is a technetium (99mTc) generator, i.e. a device used to obtain a solution for injection of sodium pertechnetate (99mTc).
When this radioactive solution is injected, it temporarily collects in certain areas of the body. The low quantity of radioactivity injected can be detected outside of the body by special cameras. Your doctor will then take an image (scan) of the concerned organ which can give him valuable information about the structure and the function of this organ.
After injection the sodium pertechnetate (99mTc) solution is used to obtain images of various body parts such as the:
- thyroid gland
- salivary glands
- appearance of stomach tissue in an abnormal location (Meckel Diverticulum)
- tear ducts of the eyes
CIS bio international
Member of IBA Molecular group of companies
The sodium pertechnetate (99mTc) solution can also be used in combination with another product to prepare another radiopharmaceutical medicine. In this case, please refer to the corresponding package leaflet.
The nuclear medicine doctor will explain to you what type of examination will be performed with this product.
The use of sodium pertechnetate (99mTc) solution does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the radiopharmaceutical outweighs the risk due to radiation.
2. What you need to know before the sodium pertechnetate (99mTc) solution obtained with Tekcis is used
The sodium pertechnetate (99mTc) solution obtained with Tekcis must not be used:
• if you are allergic to sodium pertechnetate or any of the other ingredients of this medicine(listed in section 6).
Take special care with the sodium pertechnetate (99mTc) solution obtained with Tekcis:
Inform your nuclear medicine doctor in the following cases:
• if you suffer from allergies, as a few cases of allergic reactions have been observed after administration of sodium pertechnetate (99mTc) solution,
• if you are pregnant or believe you may be pregnant,
« if you are breast-feeding,
• if you are under 18 years old.
Before administration of sodium pertechnetate (99mTc) solution you should:
- drink plenty of water before the start of the examination in order to urinate as often as possible during the first hours after the study.
Children and teenagers
Please talk to your nuclear medicine doctor if you are under 18 years old.
Other medicines and sodium pertechnetate (99mTc) solution
This medicinal product is authorised in the Member States of the EEA under the following names:
|
Country |
Product name |
|
Austria |
Tekcis 2-50 GBq Radionuklidgenerator |
|
Belgium |
Tekcis 2-50 GBq generateur radiopharmaceutique Tekcis 2-50 GBq radionuclide generator Tekcis 2-50 GBq Radionuklidgenerator |
|
Cyprus |
Tekcis 2-50 GBq Y£vvr)Tpia padiovouKAidiou |
|
Czech Republic |
Tekcis 2-50 GBq radionuklidovy generator |
|
Denmark |
Tekcis 2-50 GBq radionuklidgenerator |
|
Estonia |
Tekcis 2-50 GBq radionukliidgeneraator |
|
Finland |
Tekcis 2-50 GBq radionuklidigeneraattori |
|
France |
Tekcis 2-50 GBq generateur radiopharmaceutique |
|
Germany |
Tekcis 2-50 GBq Radionuklidgenerator |
|
Greece |
Tekcis 2-50 GBq yEvvqTpia paSiovouxAidiou |
|
Hungary |
Tekcis 2-50 GBq radioaktiv izotop generator |
|
Ireland |
Tekcis 2-50 GBq radionuclide generator |
|
Italy |
Tekcis 2-50 GBq generatore di radionuclidi |
|
Latvia |
Tekcis 2-50 GBq radionuklTdu generators |
|
Lithuania |
Tekcis 2-50 GBq radionuklidq generatorius |
|
Luxembourg |
Tekcis 2-50 GBq generateur radiopharmaceutique |
|
Netherlands |
Tekcis 2-50 GBq radionuclide generator |
|
Norway |
Tekcis 2-50 GBq radionuklidegenerator |
|
Portugal |
Tekcis 2-50 GBq gerador de radionuclidos |
|
Slovenia |
Tekcis, 2-50 GBq radionuklidni generator |
|
Spain |
Tekcis 2-50 GBq generador de radionuclido |
|
Sweden |
Tekcis 2-50 GBq radionuklidgenerator |
|
United Kingdom |
Tekcis 2-50 GBq radionuclide generator |
This leaflet was last revised on 11/2012.
The following information is intended for medical or healthcare professionals only:
The complete SmPC of Tekcis is provided as a separate document in the product package, with the objective to provide healthcare professionals with other additional scientific and practical information about the administration and use of this radiopharmaceutical.
Please refer to the SmPc (SmPc should be included in the box).
5. How Tekcis is stored
You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.
6. Contents of the pack and other information What Tekcis contains
- The active substance is: sodium pertechnetate (99mTc).
- The other ingredients are: sodium chloride, sodium nitrate and water for injection. What Tekcis looks like and contents of the pack
You will not be required to obtain or handle this medicine.
Marketing Authorisation Holder and Manufacturer
CIS bio international B.P. 32
F-91192 Gif sur Yvette Cedex
Manufacturer
CIS bio international B.P. 32
F-91192 Gif sur Yvette Cedex
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the interpretation of the images:
- methotrexate, a medicine to treat cancer, severe joint inflammations and psoriasis
- atropine, used for example :
- to reduce stomach, bowel or gall bladder spasms
- to reduce pancreas secretions
- in ophthalmology
- before administering an anaesthesia
- to treat reduced heart beat or
- as an antidote
- isoprenaline, a medicine to treat reduced heart beat
- pain killers
- laxatives
- contrast-enhanced studies (e.g. barium) and upper Gl examination
- antithyroid agents (e.g. carbimazole or other imidazole derivatives such as propylthiouracil), salicylates, steroids, sodium nitroprusside, sodium sulfobromophtalein, perchlorate)
- phenylbutazone
- expectorants
- natural or synthetic thyroid preparations (e.g. sodium thyroxine, sodium liothyronine, thyroid extract)
- amiodarone
- benzodiazepines, lithium
- intravenous contrast agents
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given this medicine.
You must inform the nuclear medicine doctor before the administration of sodium pertechnetate (99mTc) solution if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding.
When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.
If you are pregnant,
The nuclear medicine doctor will only administer this product during pregnancy if a benefit is expected which would outweigh the risks.
If you are breast-feeding,
Please ask your nuclear medicine doctor, as he/she may advise you to stop doing so until the radioactivity has left your body. This takes about 12 hours after the administration. The expressed milk should be discarded. Please ask your nuclear medicine doctor when you can resume breast-feeding.
Driving and using machines
It is considered unlikely that sodium technetium (99mTc) solution will affect your ability to drive or to use machines.
Sodium pertechnetate solution contains 3.6 mg/mL of sodium. Depending on the volume injected, the limit of 1 mmol (23 mg) of sodium per dose administered may be exceeded. This must be taken into account if you are on a low-salt diet.
3. How the sodium pertechnetate (99mTc) solution obtained with Tekcis is used
There are strict laws on the use, handling and disposal of radiopharmaceutical products. Tekcis will only be used in special controlled areas. This product will only be handled and given to you by people who are trained and qualified to use it safely. These persons will take special care for the safe use of this product and will keep you informed of their actions.
The nuclear medicine doctor supervising the procedure will decide on the quantity of sodium pertechnetate (99mTc) solution to be used in your case. It will be the smallest quantity necessary to get the desired information.
The quantity to be administered usually recommended for an adult ranges from 2 to 400 MBq (megabecquerel, the unit used to express radioactivity).
Use in children and adolescents,
In children and adolescents, the quantity to be administered will be adapted to the child’s body mass.
Administration of sodium pertechnetate (99mTc) solution and conduct of the procedure
Depending on the purpose of the examination, the product will be administered by injection into an arm vein or may be instilled into the eyes in the form of drops.
One administration is sufficient to conduct the test that your doctor needs.
The nuclear medicine doctor will inform you if you need to take any special precautions after receiving this medicine. Contact your nuclear medicine doctor if you have any questions.
After administration of sodium pertechnetate (99mTc) solution you should:
- avoid any close contact with young children and pregnant women for the 12 hours following the injection
- urinate frequently in order to eliminate the product from your body
- After injection, you will be offered a drink and asked to urinate immediately preceding the test.
Duration of the procedure
Your nuclear medicine doctor will inform you about the usual duration of the procedure.
Scans can be performed at any time, between the time of injection and for up to 24 hours after the injection, depending on the type of examination.
If you have been given more sodium pertechnetate (99mTc) solution obtained with Tekcis than you should:
An overdose is almost impossible, because you will only receive a single dose of sodium pertechnetate (99mTc) solution precisely controlled by the nuclear medicine doctor supervising the procedure.However, in the case of an overdose, you will receive the appropriate treatment. In particular, the nuclear medicine doctor in charge of the procedure may recommend that you drink plenty of fluids to remove the traces of radioactivity from your body.
Should you have any further question on the use of this product, please ask the nuclear medicine doctor who supervises the procedure.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Frequency unknown, from the data available
- allergic reactions, with symptoms such as
skin rash, itching hives
swelling at various locations, e.g. of the face
shortage of breath
erythema
coma
- circulatory reactions, with symptoms such as
rapid heart beat, slow heart beat
fainting
blurred vision
dizziness
headache
flushing
- gastrointestinal disorders, with symptoms such as
vomiting
nausea
diarrhoea
- injection site reactions, with symptoms such as
skin inflammation
pain
swelling
erythema
This radiopharmaceutical will deliver low amounts of ionising radiation with very low risk of cancer and hereditary abnormalities.
If you get any side effects talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet.
P6409pA
11/2012
5